Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

20155,843 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Johns Hopkins University

Bernard Escudier · Institut Gustave Roussy

Ray McDermott · Hadassah Medical Center

Saby George · Roswell Park Comprehensive Cancer Center

Hans J. Hammers · Sidney Kimmel Comprehensive Cancer Center

Sandhya Srinivas · Cancer Prevention Institute of California

Scott S. Tykodi

Abstract

Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).

Topics & Keywords

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 19, pp. 1803-1813

DOI: 10.1056/nejmoa1510665

Field-Weighted Citation Impact: 468.41